Cerenome reported a significantly widened operating loss for the second quarter of 2026 as the company rebranded from Plus Therapeutics and accelerated its integrated CNS oncology platform. Results reflect increased R&D investment for REYOBIQ radiotherapies and the commercial expansion of its CNSide diagnostic assay.
Key Highlights
- Operating loss increased to $9.1 million from $1.5 million in the prior-year period, driven by clinical trial progression.
- Grant revenue fell to $0.41 million compared to $1.39 million in Q2 2025 as the CPRIT funding cycle progressed.
- Cash, cash equivalents, and investments totaled $8.6 million as of June 30, 2026, maintaining liquidity levels from year-end 2025.
- Contracted commercial payer coverage for the CNSide platform reached the year-end target of 150 million covered lives ahead of schedule.